Clinical Feature: Update on managing dyslipidemiaA review of the updated Canadian Cardiovascular Society guidelines for dyslipidemia management. Edoxaban (Lixiana) approved in CanadaFourth direct-acting oral anticoagulant expected to reach Canadian market in early 2017. Relative cardiovascular safety of celecoxib confirmed COX-2 inhibitor is ‘non-inferior’ to ibuprofen and naproxen, trial shows Anticoagulant antidote works Beyond statins: What you need to know about alternative lipid-lowering agents Wrist-worn heart monitors not always accurate Validation ‘imperative’ for serious clinical use, researchers say Case Report: A patient with familial dyslipidemia fails to respond to statins Got patients with a-fib? You need to read this Recent studies evaluate biomarkers for risk assessment and compare oral anticoagulants Pharmacist-directed dyslipidemia care improves cholesterol management Pharmacist prescribing and monitoring of lipid-lowering therapy enables more patients with uncontrolled dyslipidemia to reach LDL-C targets. A heart attack is hard on younger patients’ sex life Women suffer more than men in the year after an acute MI, study finds First Previous 43 44 45 46 47 Next Last
